PharmEasy is a consumer healthcare “super app” that provides consumers with on-demand, home delivered access to a wide range of prescription, OTC pharmaceutical, other consumer healthcare products, comprehensive diagnostic test services, and teleconsultations thereby serving their healthcare needs.
PharmEasy is India’s leading digital Healthcare Platform. It focuses on simplifying healthcare. The company provides services like Ordering Medicine, Healthcare Products and Diagnostics Tests.
For buying unlisted shares of API Holdings (PharmEasy) or any other Unlisted/ Delisted Shares, please call Dharawat Securities on 8108303330
PharmEasy has evolved from being just a medicine providing platform to a wellness partner by building a sustainable healthcare ecosystem. This initiative is based on the belief that doing so would give its consumers 360-degree wellness support. It offers 1 lakh+ medicines and health products across various categories through its retail partners which are spread across the country.
PharmEasy, one of India’s leading platforms for healthcare solutions, aims to build a more holistic approach towards wellness for its customers in their journey of achieving good health.
API Holdings owns an umbrella of brands including PharmEasy, Thyrocare, Docon, Retailio, and Aknamed.
PharmEasy Unlisted Shares Details-
|Total Available Shares:||10000+|
|Face Value:||Re 1 Per Equity Share|
|Lot Size:||100 Shares|
|Current Unlisted Share Price:||Best rate in market|
API Holdings generates revenue from three segments –
Sale of Products: Sells pharma, over-the-counter, private label medical products, surgical products and consumables sourced from pharmaceutical companies or wholesalers to retailers, chemists and institutions.
Sale of Services: Derives revenue from sale of services from diagnostics, advertisement and lead generation for doctors by its B2B m
Other operating revenue: This includes providing last-mile delivery services to fulfilling orders on the platform, and lease of electronic medical records and practice management software and hardware to doctors.
The company provides health services ranging from teleconsultation to radiology tests to home delivery of medical products and devices.
In a bid to diversify its operations, the firm had acquired Thyrocare Technologies, India’s largest diagnostic test provider by volumes, in September.
API Holdings’ consolidated revenue jumped more than threefold to Rs 2,335 crore in the financial year ended March 2021. Losses, however, have also widened to Rs 636 crore during the period.
But multiple acquisitions have strengthened the company’s balance sheet over the last one year. Its pro forma consolidated revenue touched Rs 4,363 crore for 2020-21, nearly twice the group’s consolidated revenues. Pro forma losses widened to Rs 1,549 crore in the year.
For the three months ended June 30, the proforma gross merchandise value or the total monetary value of all sales for the company stood at ₹ 3,026 crore.
Company Background –
Founded in 2015 by Dharmil Sheth and Dhaval Shah, PharmEasy currently claims to connect more than 60,000 brick-and-mortar pharmacies and 4,000 doctors across 16,000 zip codes across the country. The start-up also claims to have served more than 20 million customers.
PharmEasy said it does not have an identifiable promoter. Some of its largest investors include South African Internet holding firm Naspers and Singaporean investment firm Temasek which hold 12.04% and 10.8% shares, respectively.
Key Numbers From PharmEasy’s Draft IPO Prospectus
Active Pharmacies: 87,159
Prescribing doctors: 4,617
E-consultations conducted in FY21: 34 lakh
Digital prescriptions generated: 1.07 crore
Active wholesalers: 3,261
Registered users on PharmEasy: 2.5 crore
The online pharmacy start-up was last valued at $5.6 billion (Rs 42,197.79 crore) in a Rs 2,635.22-crore pre-IPO round in October.
To date, PharmEasy has raised over $1.2 billion in equity and debt funding and its last significant deal was the $600-million acquisition of diagnostics chain Thyrocare in June this year. PharmEasy was also the first unicorn in the online pharmacy start-up, achieving the coveted status in April 2021.
Based on API Holdings’ current suite of product and service offerings, the target market is expected to be $100 billion (Rs 7.5 lakh crore) by 2025, the DRHP said citing RedSeer Research.
PharmEasy Files For Rs 6,250 Crore IPO – November 2021
Digital healthcare platform PharmEasy filed for an initial public offering (IPO) of up to Rs 6,250 crore ($842.43 million), becoming the latest startup in the country to pursue a domestic stock listing. API Holdings Ltd, PharmEasy’s parent, may also consider a further issue of equity shares via a private placement of up to Rs 1,250 crore, the company said in its draft red herring prospectus dated November 8.
PharmEasy intends to use the IPO proceeds to invest in three core areas, including marketing and promotional activities, supply chain infrastructure and fulfilment, and for upgrading its tech infrastructure.
Morgan Stanley India, BoFA Securities India, Kotak Mahindra Capital, JM Financial and Citigroup Global Markets India are appointed as lead bankers for the IPO.